Neurocentria, Inc.
7
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
28.6%
2 terminated/withdrawn out of 7 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Role: lead
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
Role: lead
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
Role: collaborator
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
Role: lead
Comparison of MMFS Dosages in Older Adults
Role: lead
Efficacy and Safety of MMFS in Early AD
Role: lead
L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD
Role: collaborator
All 7 trials loaded